Fredun Pharmaceuticals reported a 97% surge in net profit for Q2 FY27, with revenue jumping 84%. The blockbuster growth is driven by new pet wellness brands and capacity expansion, though rising debt levels warrant attention.
For Fredun Pharmaceuticals, the September quarter was about proving its ambitious pivot from a traditional drugmaker to a branded healthcare platform could deliver explosive growth. The company's consolidated net profit nearly doubled year-on-year, crossing ₹18.5 crore on an 84% revenue surge to ₹267.6 crore.
The numbers show a business accelerating sharply. Profit grew 41% sequentially, outpacing a 17% rise in revenue, as net profit margin expanded by 110 basis points to 6.9%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
Metric
CurrentQ2 FY27 (Sep 2026)
PreviousQ1 FY27 (Jun 2026)
Revenue (₹ Cr)
267.63
228.25
Profit (₹ Cr)
18.57
13.13
Net Profit Margin
6.9%
5.8%
The push into pet care
Growth came from both the core formulations business and newer, higher-margin brands. Management, cited by Multibagg.ai, said pet care, mobility, nutrition and dermaceuticals are in a high-growth phase. The company launched 16 new pet wellness products and a digital platform called PAWTALKS, according to Stockfin.ai.
This strategic shift is capital-intensive. Employee costs rose 28% quarter-on-quarter to support expansion, and depreciation more than doubled year-on-year as new capacity came online. A 40,000 sq. ft. plant at Palghar became operational in October 2026.
The cost of growth
Funding this expansion has meant taking on more debt. Long-term borrowings jumped nearly sixfold to ₹56.31 crore in FY26, reports MarketsMojo. Interest costs have risen 28.5% over the trailing nine months. The debt-to-equity ratio stands at 0.84.
The interest coverage ratio provides some comfort at 4.82 times, but the rising leverage is a clear trade-off for today's growth. Management has guided for annual capital expenditure of ₹30-40 crore for the next few years.
A muted market reaction
Despite the stellar print, the stock fell 1.1% on the results day, underperforming the broader market. MarketsMojo notes the stock trades at a premium valuation, with minimal institutional holding at just 4.13%.
The board's approval to list on the National Stock Exchange aims to broaden the investor base and improve liquidity. For now, the market seems to be weighing the impressive growth trajectory against the rising balance sheet risk.
Key Points
Consolidated net profit surged 96.9% year-on-year to ₹18.57 crore, with revenue up 84.2% to ₹267.63 crore.
Growth is driven by a strategic expansion into high-margin pet care and consumer wellness brands, alongside the core pharmaceuticals business.
Debt has risen sharply to fund capacity expansion, with long-term borrowings increasing nearly sixfold in FY26.
The stock's reaction was muted despite the strong operational performance, reflecting concerns over valuation and rising leverage.
“
Hexa Perspective
Fredun's quarter demonstrates successful execution of its growth plan, with new brands gaining traction and margins improving. The 30-35% blended revenue CAGR guidance for the next three years, noted in prior quarters, appears within reach.
The sustainability of this growth, however, is now tied to managing the increased financial leverage. The company must successfully integrate its pet care acquisitions and scale new products to generate the cash flows needed to service its debt. Investors are right to watch the interest coverage ratio as closely as the top-line growth number.
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
Frequently asked questions
What were Fredun Pharmaceuticals' Q2 FY27 results?
For Q2 FY27 (quarter ended September 2026), Fredun Pharmaceuticals reported a consolidated net profit of ₹18.57 crore, a 96.9% increase year-on-year. Revenue from operations surged 84.2% to ₹267.63 crore, demonstrating exceptionally strong growth across its business segments.
Why did Fredun Pharmaceuticals' profit nearly double in Q2 FY27?
Fredun Pharma's profit nearly doubled due to an 84% surge in revenue, driven by robust demand in its core pharmaceutical formulations and a high-growth phase in newer segments like pet care, nutrition, and dermaceuticals. Improved operational efficiency also expanded the net profit margin.
What is Fredun Pharmaceuticals' debt position after Q2 FY27?
Fredun Pharmaceuticals' debt has risen significantly to fund expansion. According to MarketsMojo, long-term borrowings jumped to ₹56.31 crore in FY26 from ₹9.61 crore the previous year. The company's consolidated debt-to-equity ratio stands at 0.84.
What is Fredun Pharma's guidance for future growth?
Management has previously guided for a blended revenue compound annual growth rate (CAGR) of 30-35% over the next three to four years. This growth is expected to be driven by new-age consumer brands growing at 35-45% and legacy formulations growing at 15-20%.
Did Fredun Pharma launch any new products in Q2 FY27?
Yes, Fredun Pharma is actively expanding its product portfolio. According to Stockfin.ai, the company highlighted 16 new pet wellness products and launched a digital knowledge platform called PAWTALKS for animal healthcare during this period.
What are Fredun Pharmaceuticals' capex plans?
Fredun Pharma has significant capital expenditure plans to become one of India's largest single-location manufacturing units. Management guidance, cited by EquityEdge Research, points to ₹30-40 crore of capex in FY27, with a similar annual outlay planned for the next two years.
How did the stock market react to Fredun Pharma's Q2 results?
The stock declined 1.07% on the day following the Q2 FY27 results announcement, underperforming the broader market. MarketsMojo noted this muted reaction despite the strong operational numbers, possibly reflecting concerns over premium valuation and rising debt.
What is the status of Fredun Pharma's NSE listing?
Fredun Pharmaceuticals' board has approved a proposal to apply for listing and trading of its equity shares on the National Stock Exchange (NSE). This move is intended to increase stock liquidity and visibility among a broader set of investors.
Fredun Pharmaceuticals Q2 profit drop
Fredun Pharmaceuticals did not experience a profit drop in Q2 FY27. On the contrary, its consolidated net profit surged 96.9% year-on-year to ₹18.57 crore, marking a near-doubling of profitability for the quarter ended September 2026.
Fredun Pharmaceuticals Q2 net profit
Fredun Pharmaceuticals' consolidated net profit for Q2 FY27 (September 2026 quarter) was ₹18.57 crore. This represents a massive 96.9% increase compared to the ₹9.43 crore net profit reported in the same quarter of the previous fiscal year.
Fredun Pharma September quarter profit
Fredun Pharmaceuticals' profit for the September 2026 quarter (Q2 FY27) was ₹18.57 crore on a consolidated basis. This is a 96.9% year-on-year increase from the profit of ₹9.43 crore in the September 2025 quarter.
Fredun Pharmaceuticals FY27 Q1 earnings
Fredun Pharmaceuticals' Q1 FY27 (June 2026 quarter) earnings showed a net profit of ₹13.13 crore on revenue of ₹228.25 crore. This set a strong foundation for the even more robust growth seen in the subsequent Q2 FY27 results.
Fredun Pharmaceuticals Q2 FY27 results August 2026
Fredun Pharmaceuticals announced its Q2 FY27 results for the period ended September 2026 in November 2026. The results, declared on November 14, 2026, showed a net profit of ₹18.57 crore, up 96.9% year-on-year, and revenue of ₹267.63 crore, up 84.2%.
